Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
7 Cheap Biotech Stocks to Buy Now
06:00pm, Thursday, 19'th May 2022
These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on Inves
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
06:57pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
03:20pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
04:05pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
04:08pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
Orphazyme, Y-mAbs Therapeutics top healthcare gainers; ProQR, Senseonics lead losers pack
03:01pm, Friday, 11'th Feb 2022 Seeking Alpha
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (VTGN) +8%.Losers: ProQR Therapeutics PRQR -72%
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript
03:14am, Friday, 11'th Feb 2022 Seeking Alpha
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates
10:55pm, Thursday, 10'th Feb 2022 Zacks Investment Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript
10:14pm, Thursday, 10'th Feb 2022
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript
VistaGen Therapeutics GAAP EPS of -$0.05 beats by $0.02, revenue of $0.36M beats by $0.11M
09:32pm, Thursday, 10'th Feb 2022 Seeking Alpha
VistaGen Therapeutics press release (VTGN): Q3 GAAP EPS of -$0.05 beats by $0.02.Revenue of $0.36M (+16.1% Y/Y) beats by $0.11M.At December 31, 2021, the Company had cash and
VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
09:20pm, Thursday, 10'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffer
VistaGen Therapeutics Q3 2022 Earnings Preview (NASDAQ:VTGN)
10:35pm, Wednesday, 09'th Feb 2022 Seeking Alpha
VistaGen Therapeutics (NASDAQ:VTGN) is scheduled to announce Q3 earnings results on Thursday, February 10th, after market close.The consensus EPS Estimate is -$0.07 (flat Y/Y) and…
VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
01:00pm, Monday, 07'th Feb 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicine
VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
08:00am, Monday, 07'th Feb 2022
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines
Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline
08:01pm, Thursday, 03'rd Feb 2022 Zacks Investment Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
